World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   1048 records for 281 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusMain ID Public TitleDate of Registration
Not recruitingNCT02231047
64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings
28/08/2014
Not recruitingNCT02226120
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
25/08/2014
Not recruitingNCT02208609
Zinc Bioavailability From Amaranth-enriched Maize Tortillas
01/08/2014
Not recruitingNCT02203890
Normative State and Variation in Growth, Hematology, Hydration, Oxidation, Infection, Inflammation, Guatemalan Children
25/07/2014
AuthorisedEUCTR2013-004148-49-HU
RANDOMIZED STUDY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-004148-49-DERANDOMIZED STUDY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS06/06/2014
06/06/2014
RecruitingCTRI/2014/04/004518
To assess long term efficacy, safety, tolerability and usability of Secukinumab in patients with active Rheumatid Artheritis
02-04-2014
AuthorisedEUCTR2013-001939-47-IT
Reformulated raltegravir (1200 mg) once a day versus raltegravir (400 mg) twice a day in treatment-naïve patients
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-001939-47-PTReformulated raltegravir (1200 mg) once a day versus raltegravir (400 mg) twice a day in treatment-naïve patients24/03/2014
28/02/2014
RecruitingNCT02075840
ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
27/02/2014
AuthorisedEUCTR2013-003331-30-AT
A study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-003331-30-FIA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.18/02/2014
AuthorisedEUCTR2013-003331-30-ITA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.18/02/2014
AuthorisedEUCTR2013-003331-30-NLA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.04/03/2014
AuthorisedEUCTR2013-003331-30-DEA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.25/02/2014
AuthorisedEUCTR2013-003331-30-ESA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.07/03/2014
AuthorisedEUCTR2013-003331-30-PTA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.25/02/2014
AuthorisedEUCTR2013-003331-30-PLA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.12/03/2014
AuthorisedEUCTR2013-003331-30-GRA study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.24/03/2014
17/02/2014
Not recruitingNCT02044107
The Effectiveness of Co-packaging With Zinc to Improve Treatment of Diarrhea and Pneumonia in Guatemala
21/01/2014
    
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history